Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 1410-1414, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okabe, R.
Right arrow Articles by Nishizawa, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okabe, R.
Right arrow Articles by Nishizawa, Y.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2001;47:1410-1414.)
© 2001 American Association for Clinical Chemistry, Inc.

Articles

Clinical Evaluation of the Elecsys ß-CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides

Reiko Okabe1,3, Kiyoshi Nakatsuka1, Masaaki Inaba1a, Takami Miki2, Hiroshi Naka2, Hideki Masaki1, Atushi Moriguchi3 and Yoshiki Nishizawa1

Departments of
1 Metabolism, Endocrinology and Molecular Medicine and
2 Geriatric Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
3 Hanwa Second Senboku Hospital, 3176, Fukai Kitamachi, Sakai City, Osaka 599-8271, Japan.

aAddress correspondence to this author at: Second Department of Internal Medicine, Osaka City University Medical School, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Fax 81-6-6645-3808; e-mail inaba-m{at}med.osaka-cu.ac.jp.

Background: The Elecsys ß-CrossLaps serum assay measures type I collagen degradation fragments (ß-CTx) that contain the ß-isomerized octapeptide EKAHD-ß-GGR. We investigated the analytical performance of the assay and changes in ß-CrossLaps in patients with metabolic bone diseases.

Methods: The electrochemiluminescent sandwich immunoassay uses two monoclonal antibodies directed against different regions of the linear EKAHD-ß-GGR.

Results: ß-CrossLaps (ß-CTx) immunoreactivity was stable in serum and plasma stored at 4 °C for 24 h or at room temperature for 4 h, and it did not decrease appreciably in samples stored at -30 °C for 12 weeks. Nine cycles of repeated freezing-thawing did not affect serum ß-CTx. The intra- and interassay imprecision (CVs) for four samples was <=2.6% (n = 10) and <=4.1% (n = 10), respectively. The mean day-to-day biological variation (CV) was 20% in 10 postmenopausal women (n = 10 days). Serum ß-CTx and osteocalcin were correlated in patients with hyperparathyroidism (r = 0.796; P <0.0001; n = 28), chronic renal failure on hemodialysis (r = 0.784; P = 0.0003; n = 16), hypoparathyroidism (r = 0.950; P = 0.0001; n = 11), and pseudohypoparathyroidism (r = 0.987; P = 0.130; n = 4). Serum ß-CTx decreased by 47.4% ± 8.8% (mean ± SD) and 60.7% ± 6.5% at 3 and 6 months, respectively, after initiation of estrogen replacement therapy in 34 women. These decreases were greater than the decreases in urinary excretion of deoxypyridinoline (31.8% ± 3.9% and 38.1% ± 4.4%, respectively) or pyridinoline cross-linked C-terminal telopeptide of type I collagen (15.9% ± 3.9% and 16.9% ± 4.6%, respectively).

Conclusions: The Elecsys ß-CrossLaps serum assay provides a potentially useful tool for assessing bone resorption state, including its response to estrogen replacement therapy.




The following articles in journals at HighWire Press have cited this article:


Home page
 The Journal of RheumatologyHome page
S. W. SYVERSEN, R. LANDEWE, D. van der HEIJDE, J. M. BATHON, M. BOERS, V. P. BYKERK, O. FITZGERALD, D. D. GLADMAN, P. GARNERO, P. GEUSENS, et al.
Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers
J Rheumatol, August 1, 2009; 36(8): 1769 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 The Journal of RheumatologyHome page
E. K. LI, L. S. TAM, J. F. GRIFFITH, T. Y. ZHU, T. K. LI, M. LI, K. C. WONG, M. CHAN, C. W. LAM, F. S. CHU, et al.
High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with Systemic Lupus Erythematosus
J Rheumatol, August 1, 2009; 36(8): 1646 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 The Journal of RheumatologyHome page
S. W. SYVERSEN, G. L. GOLL, D. van der HEIJDE, R. LANDEWE, P. I. GAARDER, S. ODEGARD, E. A. HAAVARDSHOLM, and T. K. KVIEN
Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression
J Rheumatol, February 1, 2009; 36(2): 266 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Maeno, M. Inaba, S. Okuno, T. Yamakawa, E. Ishimura, and Y. Nishizawa
Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients
Clin. Chem., December 1, 2005; 51(12): 2312 - 2317.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. R. Reid, J. Lucas, D. Wattie, A. Horne, M. Bolland, G. D. Gamble, J. S. Davidson, and A. B. Grey
Effects of a {beta}-Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5212 - 5216.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.